GILEAD SCIENCES INC raised its 2026 sales forecast to $30.4 billion despite projecting an annual loss from recent acquisition costs. The drugmaker increased its estimate for HIV prevention drug Yeztugo sales to $1 billion from a previous $800 million. Strong HIV portfolio growth offsets a projected $0.65 to $1.05 per share loss tied to three biotech acquisitions.

HIV Portfolio Drives Revenue Beat